Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

Hunan Province Tumor Hospital

Status: Enrolling

Conditions: Non Small Cell Lung Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT04324125

CRONUS

Details and patient eligibility

About

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.

Full description

Main enrolled criteria:

Her2 insertion advanced NSCLC Her 2 amplification advanced NSCLC Failed with standard chemotherapy No history of PD-1/ PD-L1 antibody using

Enrollment: 70 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
• HER 2 Insertion or Amplification
• First Diagnosis and Treatment
• Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody

Exclusion criteria

• Patients received antitumor treatment before
• Patients with contraindication of chemotherapy
• Pregnant or breast feeding women